<DOC>
	<DOCNO>NCT02886897</DOCNO>
	<brief_summary>Background : Combinations dendritic cytokine-induced killer cell ( D-CIK ) base adoptive immunotherapy anti-PD-1 antibody may enhance immune response stop cancer cell grow . Objective : Phase II clinical trial investigate safety , clinical activity toxicity combination D-CIK anti-PD-1 antibody patient treatment-refractory solid tumor . Methodology : Phase II clinical trial patient advance metastatic hepatocellular carcinoma , renal cell carcinoma , bladder cancer , colorectal cancer , non-small-cell lung cancer , breast cancer solid cancer . The D-CIK isolated peripheral blood participant , activate , expand incubated anti-PD-1 antibody infusion . The enough number ( 1.0-1.5 *10^10 cell ) D-CIK infuse back participant .</brief_summary>
	<brief_title>A Study Combinations D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors</brief_title>
	<detailed_description>Heparinized peripheral blood obtain participant 2-week period . PBMCs separate Ficoll-Hypaque gradient centrifugation , suspend X-VIVO 15 serum-free medium , culture 1000 U/ml rhIFN-γfor first 24 h , follow stimulation 100 ng/ml OKT3 , 1000 U/ml rhIL-2 100 U/ml IL-1α activate CIK.Dendritic cell incubate CIK . Fresh medium contain 1000 U/ml rhIL-2 add every 2 day cell density maintain 2×10^6 cells/mL.D-CIK harvest , wash , resuspend culture 14 day . Before cell transfer , D-CIK incubate anti-PD-1 antibody , fraction D-CIK collect assess number , phenotype , viability cell , test possible contamination bacteria , fungi , endotoxin . Then , autologous D-CIK ( 1.0-1.5*10^10 cell ) transfer patient via intravenous infusion . Generally , participant receive least 4 cycle treatment 2-week interval receive dos disease progression occur . If participant disease-stable , additional cycle maintenance treatment eligible . Participants evaluate safety , clinical activity toxicity . The primary end point objective response participant time D-CIK anti-PD-1 infusion assess RECIST . Peripheral blood patient also assess related cytokine use ELISPOT assay . Additional , investigator evaluate tumor marker participant clinical response/non-response immunohistochemical stain tumor section previous diagnostic therapeutic biopsy sample determine predictive biomarker may use future study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Participantswith treatmentrefractory advance hepatocellular carcinoma , renal cell carcinoma , bladder cancer , colorectal cancer , nonsmallcell lung cancer , breast cancer solid cancer . Age 18 75 year . Willing sign durable power attorney . Able understand sign Informed Consent Document . Life expectancy great three month . An Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Patients gender must willing practice birth control time enrollment study four month receive preparative regimen . Adequate organ function . Serology : Seronegative HIV antibody . Women childbearing potential must negative pregnancy test potentially dangerous effect preparative chemotherapy fetus . Hematology : WBC ( &gt; 3000/mm ( 3 ) ) . Platelet count great 100,000/mm ( 3 ) . Hemoglobin great 8.0 g/dl . Chemistry : Serum ALT/AST less equal 2.5 time upper limit normal . Serum creatinine less equal 1.6 mg/dl . Total bilirubin less equal 1.5 mg/dl , except patient Gilbert 's Syndrome must total bilirubin less 3.0 mg/dl . Previous treatment antiCTLA4 antiPD1/PDL1 . Active systemic infection , coagulation disorder major medical illness cardiovascular , respiratory immune system , myocardial infarction , cardiac arrhythmia , obstructive restrictive pulmonary disease . Any form primary immunodeficiency ( Severe Combined Immunodeficiency Disease ) . History autoimmune disease Concurrent opportunistic infection ( The experimental treatment evaluate protocol depends intact immune system . Patients decrease immune competence may less responsive experimental treatment susceptible toxicity ) . Concurrent antineoplastic therapy systemic steroid therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Refractory solid tumor</keyword>
	<keyword>Dendritic Cytokine-induced killer cell</keyword>
	<keyword>Anti-PD-1 antibody</keyword>
	<keyword>Combination immunotherapy</keyword>
</DOC>